PUMA BIOTECHNOLOGY, INC. (PBYI) Operating income 2016–2025
PUMA BIOTECHNOLOGY, INC. (PBYI) annual operating income history from SEC filings — each fiscal year as reported.
$37.3MFY2025 · since FY2016: -$276.6M → $37.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $37.3M | +20.5% |
| FY2024 | $31.0M | -5.1% |
| FY2023 | $32.6M | +37.6% |
| FY2022 | $23.7M | +1738.8% |
| FY2021 | $1.3M | +104.2% |
| FY2020 | -$30.4M | +22.1% |
| FY2019 | -$39.0M | +58.8% |
| FY2018 | -$94.7M | +67.6% |
| FY2017 | -$292.4M | -5.7% |
| FY2016 | -$276.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PBYI financial trends
PBYI RevenuePBYI Net incomePBYI Net marginPBYI Gross profitPBYI Gross marginPBYI Operating marginPBYI Operating cash flowPBYI Free cash flowPBYI Capital expendituresPBYI Return on equityPBYI Stock buybacksPBYI Dividends paidPBYI Total assetsPBYI Total liabilitiesPBYI Shareholders’ equityPBYI overview →